0.00Open0.55Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover0.00%IV-5.45%PremiumJan 17, 2025Expiry Date0.63Intrinsic Value100Multiplier-6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.50Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Coherus BioSciences Stock Discussion
📊⚡️📊
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
Wednesday, 22nd January at 7:00 am
– Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate –
– Antitumor activity was observed across both viral and non-viral etiologies –
– Data support continued...
$Coherus BioSciences (CHRS.US)$
No comment yet